Shared on05 Sep 25
With both Net Profit Margin and Future P/E ratio remaining stable, analysts have kept Thyrocare Technologies’ fair value unchanged at ₹1355. What's in the News Special/Extraordinary Shareholders Meeting scheduled via postal ballot in India.
Shared on30 Jul 25Fair value Increased 33%
The significant upward revision in Thyrocare Technologies’ price target reflects higher consensus revenue growth forecasts, with fair value increasing from ₹1020 to ₹1355. What's in the News Mr. Alok Kumar Jagnani has been elevated from CFO of Thyrocare Technologies to Group CFO of API Holdings Limited and is proposed to join Thyrocare's Board as a Non-Executive Director; he will step down as CFO.
Shared on01 May 25Fair value Decreased 7.66%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 13%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on12 Mar 25Fair value Decreased 2.94%
AnalystConsensusTarget has increased profit margin from 17.5% to 19.8%.